A European evidence-based guideline for the prevention of type 2 diabetes

Research output: Contribution to journalReview articlepeer-review

Standard

A European evidence-based guideline for the prevention of type 2 diabetes. / The IMAGE Study Group; Paulweber, B.; Valensi, P.; Lindström, J.; Lalic, N. M.; Greaves, C. J.; McKee, M.; Kissimova-Skarbek, K.; Liatis, S.; Cosson, E.; Szendroedi, J.; Sheppard, K. E.; Charlesworth, K.; Felton, A. M.; Hall, M.; Rissanen, A.; Tuomilehto, J.; Schwarz, P. E.; Roden, M.; Paulweber, M.; Stadlmayr, A.; Kedenko, L.; Katsilambros, N.; Makrilakis, K.; Kamenov, Z.; Evans, P.; Gilis-Januszewska, A.; Lalic, K.; Jotic, A.; Djordevic, P.; Dimitrijevic-Sreckovic, V.; Hühmer, U.; Kulzer, B.; Puhl, S.; Lee-Barkey, Y. H.; Alkerwi, A.; Abraham, C.; Hardeman, W.; Acosta, T.; Adler, M.; Alkerwi, A.; Barengo, N.; Barengo, R.; Boavida, J. M.; Charlesworth, K.; Christov, V.; Claussen, B.; Cos, X.; Cosson, E.; Greaves, C. J. (Contributor); McIntosh, C. (Contributor).

In: Hormone and Metabolic Research, Vol. 42, No. SUPPL. 1, 13.04.2010, p. S3-S36.

Research output: Contribution to journalReview articlepeer-review

Harvard

The IMAGE Study Group, Paulweber, B, Valensi, P, Lindström, J, Lalic, NM, Greaves, CJ, McKee, M, Kissimova-Skarbek, K, Liatis, S, Cosson, E, Szendroedi, J, Sheppard, KE, Charlesworth, K, Felton, AM, Hall, M, Rissanen, A, Tuomilehto, J, Schwarz, PE, Roden, M, Paulweber, M, Stadlmayr, A, Kedenko, L, Katsilambros, N, Makrilakis, K, Kamenov, Z, Evans, P, Gilis-Januszewska, A, Lalic, K, Jotic, A, Djordevic, P, Dimitrijevic-Sreckovic, V, Hühmer, U, Kulzer, B, Puhl, S, Lee-Barkey, YH, Alkerwi, A, Abraham, C, Hardeman, W, Acosta, T, Adler, M, Alkerwi, A, Barengo, N, Barengo, R, Boavida, JM, Charlesworth, K, Christov, V, Claussen, B, Cos, X, Cosson, E, Greaves, CJ & McIntosh, C 2010, 'A European evidence-based guideline for the prevention of type 2 diabetes', Hormone and Metabolic Research, vol. 42, no. SUPPL. 1, pp. S3-S36. https://doi.org/10.1055/s-0029-1240928

APA

The IMAGE Study Group, Paulweber, B., Valensi, P., Lindström, J., Lalic, N. M., Greaves, C. J., McKee, M., Kissimova-Skarbek, K., Liatis, S., Cosson, E., Szendroedi, J., Sheppard, K. E., Charlesworth, K., Felton, A. M., Hall, M., Rissanen, A., Tuomilehto, J., Schwarz, P. E., Roden, M., ... McIntosh, C. (2010). A European evidence-based guideline for the prevention of type 2 diabetes. Hormone and Metabolic Research, 42(SUPPL. 1), S3-S36. https://doi.org/10.1055/s-0029-1240928

Vancouver

The IMAGE Study Group, Paulweber B, Valensi P, Lindström J, Lalic NM, Greaves CJ et al. A European evidence-based guideline for the prevention of type 2 diabetes. Hormone and Metabolic Research. 2010 Apr 13;42(SUPPL. 1):S3-S36. https://doi.org/10.1055/s-0029-1240928

Author

The IMAGE Study Group ; Paulweber, B. ; Valensi, P. ; Lindström, J. ; Lalic, N. M. ; Greaves, C. J. ; McKee, M. ; Kissimova-Skarbek, K. ; Liatis, S. ; Cosson, E. ; Szendroedi, J. ; Sheppard, K. E. ; Charlesworth, K. ; Felton, A. M. ; Hall, M. ; Rissanen, A. ; Tuomilehto, J. ; Schwarz, P. E. ; Roden, M. ; Paulweber, M. ; Stadlmayr, A. ; Kedenko, L. ; Katsilambros, N. ; Makrilakis, K. ; Kamenov, Z. ; Evans, P. ; Gilis-Januszewska, A. ; Lalic, K. ; Jotic, A. ; Djordevic, P. ; Dimitrijevic-Sreckovic, V. ; Hühmer, U. ; Kulzer, B. ; Puhl, S. ; Lee-Barkey, Y. H. ; Alkerwi, A. ; Abraham, C. ; Hardeman, W. ; Acosta, T. ; Adler, M. ; Alkerwi, A. ; Barengo, N. ; Barengo, R. ; Boavida, J. M. ; Charlesworth, K. ; Christov, V. ; Claussen, B. ; Cos, X. ; Cosson, E. ; Greaves, C. J. ; McIntosh, C. / A European evidence-based guideline for the prevention of type 2 diabetes. In: Hormone and Metabolic Research. 2010 ; Vol. 42, No. SUPPL. 1. pp. S3-S36.

Bibtex

@article{cb36af28f2c34cc28384d3fe32a0f5b3,
title = "A European evidence-based guideline for the prevention of type 2 diabetes",
abstract = "Background: The prevalence and socioeconomic burden of type 2 diabetes (T2DM) and associated co-morbidities are rising worldwide. Aims: This guideline provides evidence-based recommendations for preventing T2DM. Methods: A European multidisciplinary consortium systematically reviewed the evidence on the effectiveness of screening and interventions for T2DM prevention using SIGN criteria. Results: Obesity and sedentary lifestyle are the main modifiable risk factors. Age and ethnicity are non-modifiable risk factors. Case-finding should follow a step-wise procedure using risk questionnaires and oral glucose tolerance testing. Persons with impaired glucose tolerance and/or fasting glucose are at high-risk and should be prioritized for intensive intervention. Interventions supporting lifestyle changes delay the onset of T2DM in high-risk adults (number-needed-to-treat: 6.4 over 1.84.6 years). These should be supported by inter-sectoral strategies that create health promoting environments. Sustained body weight reduction by 5% lowers risk. Currently metformin, acarbose and orlistat can be considered as second-line prevention options. The population approach should use organized measures to raise awareness and change lifestyle with specific approaches for adolescents, minorities and disadvantaged people. Interventions promoting lifestyle changes are more effective if they target both diet and physical activity, mobilize social support, involve the planned use of established behaviour change techniques, and provide frequent contacts. Cost-effectiveness analysis should take a societal perspective. Conclusions: Prevention using lifestyle modifications in high-risk individuals is cost-effective and should be embedded in evaluated models of care. Effective prevention plans are predicated upon sustained government initiatives comprising advocacy, community support, fiscal and legislative changes, private sector engagement and continuous media communication.",
author = "{The IMAGE Study Group} and B. Paulweber and P. Valensi and J. Lindstr{\"o}m and Lalic, {N. M.} and Greaves, {C. J.} and M. McKee and K. Kissimova-Skarbek and S. Liatis and E. Cosson and J. Szendroedi and Sheppard, {K. E.} and K. Charlesworth and Felton, {A. M.} and M. Hall and A. Rissanen and J. Tuomilehto and Schwarz, {P. E.} and M. Roden and M. Paulweber and A. Stadlmayr and L. Kedenko and N. Katsilambros and K. Makrilakis and Z. Kamenov and P. Evans and A. Gilis-Januszewska and K. Lalic and A. Jotic and P. Djordevic and V. Dimitrijevic-Sreckovic and U. H{\"u}hmer and B. Kulzer and S. Puhl and Lee-Barkey, {Y. H.} and A. Alkerwi and C. Abraham and W. Hardeman and T. Acosta and M. Adler and A. Alkerwi and N. Barengo and R. Barengo and Boavida, {J. M.} and K. Charlesworth and V. Christov and B. Claussen and X. Cos and E. Cosson and Greaves, {C. J.} and C. McIntosh",
year = "2010",
month = apr,
day = "13",
doi = "10.1055/s-0029-1240928",
language = "English",
volume = "42",
pages = "S3--S36",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Thieme Publishing",
number = "SUPPL. 1",

}

RIS

TY - JOUR

T1 - A European evidence-based guideline for the prevention of type 2 diabetes

AU - The IMAGE Study Group

AU - Paulweber, B.

AU - Valensi, P.

AU - Lindström, J.

AU - Lalic, N. M.

AU - Greaves, C. J.

AU - McKee, M.

AU - Kissimova-Skarbek, K.

AU - Liatis, S.

AU - Cosson, E.

AU - Szendroedi, J.

AU - Sheppard, K. E.

AU - Charlesworth, K.

AU - Felton, A. M.

AU - Hall, M.

AU - Rissanen, A.

AU - Tuomilehto, J.

AU - Schwarz, P. E.

AU - Roden, M.

AU - Paulweber, M.

AU - Stadlmayr, A.

AU - Kedenko, L.

AU - Katsilambros, N.

AU - Makrilakis, K.

AU - Kamenov, Z.

AU - Evans, P.

AU - Gilis-Januszewska, A.

AU - Lalic, K.

AU - Jotic, A.

AU - Djordevic, P.

AU - Dimitrijevic-Sreckovic, V.

AU - Hühmer, U.

AU - Kulzer, B.

AU - Puhl, S.

AU - Lee-Barkey, Y. H.

AU - Alkerwi, A.

AU - Abraham, C.

AU - Hardeman, W.

AU - Acosta, T.

AU - Adler, M.

AU - Alkerwi, A.

AU - Barengo, N.

AU - Barengo, R.

AU - Boavida, J. M.

AU - Charlesworth, K.

AU - Christov, V.

AU - Claussen, B.

AU - Cos, X.

AU - Cosson, E.

A2 - Greaves, C. J.

A2 - McIntosh, C.

PY - 2010/4/13

Y1 - 2010/4/13

N2 - Background: The prevalence and socioeconomic burden of type 2 diabetes (T2DM) and associated co-morbidities are rising worldwide. Aims: This guideline provides evidence-based recommendations for preventing T2DM. Methods: A European multidisciplinary consortium systematically reviewed the evidence on the effectiveness of screening and interventions for T2DM prevention using SIGN criteria. Results: Obesity and sedentary lifestyle are the main modifiable risk factors. Age and ethnicity are non-modifiable risk factors. Case-finding should follow a step-wise procedure using risk questionnaires and oral glucose tolerance testing. Persons with impaired glucose tolerance and/or fasting glucose are at high-risk and should be prioritized for intensive intervention. Interventions supporting lifestyle changes delay the onset of T2DM in high-risk adults (number-needed-to-treat: 6.4 over 1.84.6 years). These should be supported by inter-sectoral strategies that create health promoting environments. Sustained body weight reduction by 5% lowers risk. Currently metformin, acarbose and orlistat can be considered as second-line prevention options. The population approach should use organized measures to raise awareness and change lifestyle with specific approaches for adolescents, minorities and disadvantaged people. Interventions promoting lifestyle changes are more effective if they target both diet and physical activity, mobilize social support, involve the planned use of established behaviour change techniques, and provide frequent contacts. Cost-effectiveness analysis should take a societal perspective. Conclusions: Prevention using lifestyle modifications in high-risk individuals is cost-effective and should be embedded in evaluated models of care. Effective prevention plans are predicated upon sustained government initiatives comprising advocacy, community support, fiscal and legislative changes, private sector engagement and continuous media communication.

AB - Background: The prevalence and socioeconomic burden of type 2 diabetes (T2DM) and associated co-morbidities are rising worldwide. Aims: This guideline provides evidence-based recommendations for preventing T2DM. Methods: A European multidisciplinary consortium systematically reviewed the evidence on the effectiveness of screening and interventions for T2DM prevention using SIGN criteria. Results: Obesity and sedentary lifestyle are the main modifiable risk factors. Age and ethnicity are non-modifiable risk factors. Case-finding should follow a step-wise procedure using risk questionnaires and oral glucose tolerance testing. Persons with impaired glucose tolerance and/or fasting glucose are at high-risk and should be prioritized for intensive intervention. Interventions supporting lifestyle changes delay the onset of T2DM in high-risk adults (number-needed-to-treat: 6.4 over 1.84.6 years). These should be supported by inter-sectoral strategies that create health promoting environments. Sustained body weight reduction by 5% lowers risk. Currently metformin, acarbose and orlistat can be considered as second-line prevention options. The population approach should use organized measures to raise awareness and change lifestyle with specific approaches for adolescents, minorities and disadvantaged people. Interventions promoting lifestyle changes are more effective if they target both diet and physical activity, mobilize social support, involve the planned use of established behaviour change techniques, and provide frequent contacts. Cost-effectiveness analysis should take a societal perspective. Conclusions: Prevention using lifestyle modifications in high-risk individuals is cost-effective and should be embedded in evaluated models of care. Effective prevention plans are predicated upon sustained government initiatives comprising advocacy, community support, fiscal and legislative changes, private sector engagement and continuous media communication.

UR - http://www.scopus.com/inward/record.url?scp=77951047476&partnerID=8YFLogxK

U2 - 10.1055/s-0029-1240928

DO - 10.1055/s-0029-1240928

M3 - Review article

C2 - 20391306

AN - SCOPUS:77951047476

VL - 42

SP - S3-S36

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - SUPPL. 1

ER -